

RECEIVED
CENTRAL FAX CENTER

DEC 23 2005

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/786,810
	Filing Date	February 25, 2004
	First Named Inventor	Jésus BENAVIDES et al.
	Art Unit	1617
	Examiner Name	CHONG, Yong Soo
	Attorney Docket Number	ST01023 US CNT
Total Number of Pages in This Submission	15 pgs.	

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Response to Restriction/Election requirement - 7 pgs.
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	2. Copy of the International Preliminary Examination - 7 pgs.
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature	<i>Balaram Gupta</i>		
Printed name	Balaram GUPTA		
Date	December 23, 2005	Reg. No.	40,009

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300; Total No. of Pages Transmitted: 15 pgs.)	
Signature	<i>Maribel Mendez</i>
Typed or printed name	Maribel Mendez
Date	December 23, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

Docket No.: ST01023 US CNT

RECEIVED
CENTRAL FAX CENTER

DEC 23 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
Jesus Benavides, et al.

Examiner: Chong, Yong Soo

Serial No.: 10/786,810

Art Unit: 1617

Filed: February 25, 2004

Title: Combination of a CB1 Receptor
Antagonist and of a Product which
Activates Dopaminergic
Neurotransmission in the Brain, the
Pharmaceutical Compositions
Comprising Them and Their Use in the
Treatment of Parkinson's Disease**TELEFAX CERTIFICATE**I hereby certify that this correspondence is being
transmitted via facsimile at (571) 273-8300 to the
Commissioner for Patents, Washington, D.C. 20231,
on

December 23, 2005

Date of Transmission

Signature

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**Response to Restriction/Election Requirement Under 35 U.S.C. § 121**

Sir:

This is in response to the Office Action, dated, November 30, 2005, having a response due by December 30, 2005 in the above-identified patent application. It is respectfully requested that the following provisional election, and the remarks be entered in this case.

PROVISIONAL ELECTION:

Applicants provisionally elect with traverse the invention Group VII, claims 1, 2 (in part), 10, 20, 21 (in part), 29, and 35-36, drawn to a composition comprising levodopa and a compound of formula I where R comprises an aryl group such as N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

ST01023 US CNT

-1 of 7-